Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Abcuro, Inc.
Abcuro Presents Results from Phase 2/3 MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis at GCOM 2026
March 26, 2026
From
Abcuro, Inc.
Via
Business Wire
Abcuro Announces Topline Results from the MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis
February 24, 2026
From
Abcuro, Inc.
Via
Business Wire
Abcuro Presents Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting
December 08, 2025
From
Abcuro, Inc.
Via
Business Wire
Abcuro to Present Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting
November 03, 2025
From
Abcuro, Inc.
Via
Business Wire
Abcuro Appoints George Eldridge as Chief Financial Officer
August 18, 2025
From
Abcuro, Inc.
Via
Business Wire
Abcuro Appoints Courtney Cupples as Chief Commercial Officer
June 09, 2025
From
Abcuro, Inc.
Via
Business Wire
Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting
March 11, 2025
From
Abcuro, Inc.
Via
Business Wire
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
February 12, 2025
From
Abcuro, Inc.
Via
Business Wire
Abcuro Announces Participation in Upcoming Investor Conferences
November 11, 2024
From
Abcuro, Inc.
Via
Business Wire
Abcuro Announces Participation in Upcoming Investor Conferences
August 29, 2024
From
Abcuro, Inc.
Via
Business Wire
Abcuro Appoints Sarah Boyce to its Board of Directors
July 31, 2024
From
Abcuro, Inc.
Via
Business Wire
Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
June 25, 2024
From
Abcuro, Inc.
Via
Business Wire
Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors
December 06, 2023
From
Abcuro, Inc.
Via
Business Wire
Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis
November 13, 2023
From
Abcuro, Inc.
Via
Business Wire
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline
August 17, 2023
From
Abcuro, Inc.
Via
Business Wire
Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis
May 31, 2023
From
Abcuro, Inc.
Via
Business Wire
Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis
April 03, 2023
From
Abcuro, Inc.
Via
Business Wire
Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia
October 04, 2022
From
Abcuro, Inc.
Via
Business Wire
Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells
November 05, 2021
From
Abcuro, Inc.
Via
Business Wire
Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors
October 19, 2021
From
Abcuro, Inc.
Via
Business Wire
Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress
October 06, 2021
From
Abcuro, Inc.
Via
Business Wire
Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis
June 30, 2021
From
Abcuro, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
